Exploring the clinical transition of engineered exosomes designed for intracellular delivery of therapeutic proteins.
Stem Cells Transl Med
; 13(7): 637-647, 2024 Jul 15.
Article
en En
| MEDLINE
| ID: mdl-38838263
ABSTRACT
Extracellular vesicles, particularly exosomes, have emerged as promising drug delivery systems owing to their unique advantages, such as biocompatibility, immune tolerability, and target specificity. Various engineering strategies have been implemented to harness these innate qualities, with a focus on enhancing the pharmacokinetic and pharmacodynamic properties of exosomes via payload loading and surface engineering for active targeting. This concise review outlines the challenges in the development of exosomes as drug carriers and offers insights into strategies for their effective clinical translation. We also highlight preclinical studies that have successfully employed anti-inflammatory exosomes and suggest future directions for exosome therapeutics. These advancements underscore the potential for integrating exosome-based therapies into clinical practice, heralding promise for future medical interventions.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Sistemas de Liberación de Medicamentos
/
Exosomas
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Stem Cells Transl Med
Año:
2024
Tipo del documento:
Article